<DOC>
	<DOCNO>NCT02775500</DOCNO>
	<brief_summary>The purpose Apremilast Pregnancy Exposure Registry monitor plan unplanned pregnancy expose apremilast evaluate safety medication relative specify pregnancy outcome , evaluate potential effect prenatal apremilast exposure infant health status one year age .</brief_summary>
	<brief_title>Apremilast Pregnancy Exposure Registry</brief_title>
	<detailed_description>The Apremilast Pregnancy Exposure Registry ( Registry ) United States ( U.S. ) base registry design monitor plan unplanned pregnancy expose apremilast used treat approve indication accordance current approve prescribing information , reside U.S. Canada . The goal Registry conduct observational , control prospective cohort study involve follow-up live born infant one year age . The primary objective Registry evaluate potential increase risk major birth defect , specifically pattern anomaly , apremilast expose pregnancy compare primary comparison group disease-matched unexposed pregnancy . Secondary objective evaluate potential effect exposure relative secondary comparison group healthy pregnant woman , effect exposure adverse pregnancy outcome include spontaneous abortion stillbirth , preterm delivery , reduce infant birth size , pattern minor malformation , postnatal growth live bear child one year age , incidence serious opportunistic infection malignancy live bear child one year age . The Pregnancy Exposure Registry sponsor Celgene Corporation conduct Organization Teratology Information Specialists ( OTIS ) Research Group administer investigator coordinate site locate University California , San Diego . The study plan seven year .</detailed_description>
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Psoriasis</mesh_term>
	<mesh_term>Autoimmune Diseases</mesh_term>
	<mesh_term>Arthritis , Psoriatic</mesh_term>
	<mesh_term>Apremilast</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<criteria>Pregnant</criteria>
	<gender>Female</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>pregnancy</keyword>
	<keyword>apremilast</keyword>
	<keyword>Otezla</keyword>
	<keyword>autoimmune disease</keyword>
	<keyword>psoriatic arthritis</keyword>
	<keyword>psoriasis</keyword>
	<keyword>TNF</keyword>
	<keyword>tumor necrosis factor</keyword>
	<keyword>birth outcome</keyword>
	<keyword>birth defect</keyword>
</DOC>